You are here

Hemodiyaliz tedavisi sırasında meme kanseri tanısı konan hastaların klinik özelliklerinin değerlendirilmesi

Journal Name:

Publication Year:

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Objective: The aim of the study, was to evaluate clinical features of the patients who were diagnosed as breast cancer during hemodialysis. Method: Eighteen patients with end stage renal disease who were diagnosed as breast cancer while they were receiving hemodialysis treatment of Mersin State Hospital and Süleyman Demirel University School of medicine were included in the study between June 2002-March 2006. Results: porty four percent of the patients were stage IV, %22 were in stage III, %16 were stage II and %16 stage I. Six patients received hormonotherapy, 12 patients received chemotherapy (6 adjuvant, 6 paliatif) and seven patients (4 adjuvant, 3 paliatif) received radiotherapy. pifty five percent of the patients were alive and %45 died. While six patients died as a result of breast cancer, two patients died due to progression of renal disease. Conclision: porty four percent of the patients who were diagnosed as breast cancer during hemodialysis treatment were in metastatic stage at the time of diagnosis. None of them had any screening evalution for breast cancer following the initiation of hemodialysis treatment. This finding suggests that even if the patients are suffering end stage renal disease, they should be screened for breast cancer as normal population.
Abstract (Original Language): 
Amaç: Kronik Böbrek yetmezliği (KBY) tanısı ile hemodiyaliz programında iken meme kanseri tanısı konan hastaların özelliklerinin incelenmesi amaçlandı. Metod: 2002-2009 yılları arasında Mersin Devlet Hastanesi ve Süleyman Demirel üniversitesi Tıp pakültesi Tıbbi Onkoloji ünitelerinde meme kanseri tanısı konmuş halen hemodiyaliz programında olan 18 hastanın dosyaları retrospektif olarak incelendi. Bulgular: Hastaların %44' ü Evre 4, %22'si Evre 3, %16'sı Evre 2, %16'sı Evre 1 idi. Onsekiz hastadan 6 tanesi hormonoterapi, 12 tanesi kemoterapi (6 tanesi adjuvan, 6 tanesi palyatif), 7 hasta radyoterapi (4 hasta adjuvan, 3 hasta palyatif) aldı. Hastaların yapılan son kontrollerinde % 55'i yaşıyor, % 45'i ex olmuş idi. Ex olan 8 hastanın 6 tanesi meme kanseri progresyonundan, 2 tanesi böbrek yetmezliği progresyonu ile olmuştu. Sonuç: Hemodiyaliz programı sırasında meme kanseri tanısı konan hastaların tanı anında %44'ü metastatik idi. Bu hastaların hiçbirinde diyalize başladıktan sonra meme kanseri taraması ve meme muayenesi yapılmamıştı. Bu durum bize hastalar son dönem böbrek hastaları (SDBH) olsalar dahi normal popülasyon gibi meme muayene ve taramalarının yapılmasının önemini belirtmektedir.
120-122

REFERENCES

References: 

1- Penn I.
Occuranc
e ofcancers in immunosuppressed organtransplantrecipients. ClinTranspl 1994:99-109.
2-
Matas AJ, Simmons RL, Kjelistrand CM, Büselmeier TJ, Najarian JS. increased incidance ofmalignancy during chronic renal failure. Lancet 1975; 1: 883-6
3- Gurtis JR. Cancer and patients with end-stage renal failure. Br MedJ 1982;284:69-70
4- Maisonneuve P, Agodoa L, Gellert R et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999; 354(9173): 93-99
5- Vamkavas S, Bahner U, Heidlan A . Cancer in end stage renal disease: Potential factors invoved-editorial-AmJNephrol 1998;18 (2) :89-95
6- Buccianti G, Maisonneuve P, Ravasi B, et al. Cancer among patients on renal replacement therapy :A
population based survey in Lombardy. İtaly. İnt J Cancer 1996;66:591-593
7- Inamato H, Ozaki R, Matsuzaki T, et al. incidence and mortality patterns ofmalignancy in dialysis patients. Nephron 1991 ; 59: 611-617
8- Smith RA, Cokkinides V, Eyre HJ : American Cancer society guidelines for the early detection of cancer, 2006. CA Cancer Clin J 56: 11-25, 2006
9- Wong G , Howard K , Chapman JR , Craig JC. Am J Kidney Dis. 2008 Nov; 52(5):916-29
10- Jean L. Holley, Clin J Am Soc. Nephrol 2:604-610,
2007
11- Jung Eun Lee at all. J Korean Med Sci 2009; 24 (Suppl 1): 95-101

Thank you for copying data from http://www.arastirmax.com